{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001752","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.600498+00:00","generated_at":"2026-06-05T11:48:46.860344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M","bullets":["Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.","Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).","Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.","Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.","Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001752","json":"https://secwatch.observer/filing/0001558370-24-001752.json","markdown":"https://secwatch.observer/filing/0001558370-24-001752.md","text":"https://secwatch.observer/filing/0001558370-24-001752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/acrs-20240227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:48:46.860344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3856431e5b33f2e935fe859e7a204aab60eaaf6e","claim":"Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.","evidence_excerpt":"Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022."},{"label":"Net income","value":"Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}